Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Has Average Target Price of $21.44

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned a consensus rating of “Hold” from the twenty-one analysts that are presently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $21.44.

NTLA has been the topic of a number of recent analyst reports. Wolfe Research lowered Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a research note on Wednesday, July 15th. Evercore raised shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target on the stock in a research note on Friday, August 7th. Barclays initiated coverage on Intellia Therapeutics in a report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, October 15th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, September 9th.

Insider Activity

In related news, CEO John M. Leonard sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $11.99, for a total transaction of $107,910.00. Following the completion of the transaction, the chief executive officer owned 1,138,064 shares in the company, valued at $13,645,387.36. The trade was a 0.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 3.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of NTLA. PNC Financial Services Group Inc. increased its position in shares of Intellia Therapeutics by 36.4% during the first quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock worth $46,000 after purchasing an additional 948 shares in the last quarter. Wealthfront Advisers LLC lifted its holdings in shares of Intellia Therapeutics by 7.6% during the 1st quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock valued at $185,000 after purchasing an additional 1,018 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Intellia Therapeutics by 2.7% during the 2nd quarter. Wellington Management Group LLP now owns 43,484 shares of the company’s stock valued at $736,000 after purchasing an additional 1,125 shares during the last quarter. Cyndeo Wealth Partners LLC boosted its position in shares of Intellia Therapeutics by 6.1% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 26,986 shares of the company’s stock worth $325,000 after purchasing an additional 1,556 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of Intellia Therapeutics by 289.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,144 shares of the company’s stock worth $26,000 after purchasing an additional 1,594 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $11.17 on Wednesday. Intellia Therapeutics has a fifty-two week low of $7.95 and a fifty-two week high of $18.48. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -3.33 and a beta of 1.83. The business’s 50 day moving average price is $12.05 and its 200-day moving average price is $13.02.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). The business had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $9.74 million. Intellia Therapeutics had a negative net margin of 805.75% and a negative return on equity of 64.74%. Intellia Therapeutics’s revenue was down 47.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.92) EPS. Sell-side analysts predict that Intellia Therapeutics will post -3.28 earnings per share for the current year.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $25 price target, offering a constructive counterpoint to the lower earnings forecasts. Analyst estimates
• Neutral Sentiment: Intellia plans to present at the Jefferies Global Healthcare Conference in London; the announcement did not include new clinical or financial information. Conference announcement
• Neutral Sentiment: A short-interest report claims a significant increase but lists short interest as zero shares, making the data internally inconsistent and difficult to interpret.
• Neutral Sentiment: The company reported inducement equity grants for new employees; the announcement provides no material business or clinical update. Inducement grants announcement
• Negative Sentiment: Analysts lowered projected earnings across multiple periods. The cuts reinforce concerns about Intellia’s expected losses and longer-term profitability, which may weigh on investor sentiment. Analyst estimates

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.